SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.
SK Biopharmaceuticals Co. Ltd. has received US FDA approval for its novel anti-epileptic drug Xcopri (cenobamate), for the treatment of partial onset seizures in adults, providing a new treatment option for refractory epileptic patients.
A new effective therapy for drug-resistant epilepsy has been seen as one of the most pressing unmet needs in this...